Roman Thomas, Disco Pharmaceuticals CEO
Disco debuts with €20M seed round to advance surfaceome-based platform, with support from AbbVie
Disco Pharmaceuticals has arrived with €20 million ($21.9 million) in its pockets and Big Pharma backing, with the German company aiming to advance its surface …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.